.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Analyze global market entry opportunities
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Medtronic
Boehringer Ingelheim
US Army
Cipla
Chubb
Fuji
McKinsey
QuintilesIMS
Healthtrust
Dow

Generated: July 25, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title: Sinister-3,5-disubstituted oxozolidines their preparation and use
Abstract:Preparation of S-3-X-4-(3-substituted amino-2-hydroxypropoxy)-1,2,5-thiadiazole beta adrenergic blocking agents using as starting material an optically active alkalmine in the sinister configuration, or a derivative of said alkamine, which is reacted with an 3-X-4-chloro(or RO-where R is hydrogen or an alkali metal)-1,2,5-thiadiazole. Certain3-morpholino-4-chloro(or RO-)-1,2,5-thiadiazoles and certain alkamines and their preparation also are described. Preferred alkamines are S-3,5-disubstituted oxazolidines.
Inventor(s): Weinstock; Leonard M. (Belle Mead, NJ), Tull; Roger J. (Metuchen, NJ), Mulvey; Dennis M. (Whitehouse, NJ)
Assignee: Charles E. Frosst & Co. (Kirkland, CA)
Filing Date:Dec 04, 1974
Application Number:05/529,314
Claims:1. An optically active oxazolidine in the sinister configuration having the structure: ##STR6## wherein R.sup.1 is hydroxy or R.sup.3 O-- wherein R.sup.3 is C.sub.1-16 alkylsulfonyl, benzenesulfonyl optionally having substituents selected from the group consisting of

a. an amino group,

b. 1-3 bromo groups,

c. 1-3 chloro groups,

d. a chloro and a nitro group,

e. a fluoro group,

f. a methoxy group,

g. 1-3 methyl groups and

h. a nitro group;

Z is hydrogen, benzyl, C.sub.1 -C.sub.3 alkyl, phenyl optionally having substituents selected from the group consisting of

a. 1-3- bromo groups,

b. 1-3 chloro groups,

c. 1-3 methyl groups,

d. a methoxy group and

e. 1-3 hydroxy groups,

or Z can be furfuryl; and Y is a straight or branched chain C.sub.1 -C.sub.5 alkyl or hydroxy substituted straight or branched chain C.sub.1 -C.sub.5 alkyl.

2. An oxazolidine as claimed in claim 1 wherein R.sup.1 is hydroxy.

3. An oxazolidine as claimed in claim 1 wherein R.sup.1 is R.sup.3 O--.

4. S-3-tert-butyl-5-hydroxymethyloxazolidine.

5. S-2-phenyl-3-tert-butyl-5-hydroxymethyloxazolidine.

6. S-3-tert-butyl-5-(p-toluenesulfonyloxymethyl)-oxazolidine.

7. S-3-tert-butyl-5-(p-nitrobenzenesulfonyloxy-methyl)oxazolidine.

8. S-3-tert-butyl-5-(p-bromobenzenesulfonyloxymethyl)oxazolidine.

9. An optically active 3-Y-5-hydroxymethyloxazolidine in the sinister configuration wherein Y is a straight or branched chain C.sub.1 -C.sub.5 alkyl or hydroxy substituted straight or branched chain C.sub.1 -C.sub.5 alkyl.

10. S-3-Isopropyl-5-hydroxymethyloxazolidine.

11. S-3-(2,2-dimethylpropyl)-5-hydroxymethyloxazolidine.

12. S-3-(1,1-dimethyl-2-hydroxyethyl)-5-hydroxymethyl oxazolidine.

13. An optically active 2- C.sub.1 -C.sub.3 alkyl-3-Y-5-hydroxymethyloxazolidine in the sinister configuration wherein Y is a straight or branched chain C.sub.1 -C.sub.5 alkyl or hydroxy substituted straight or branched chain C.sub.1 -C.sub.5 alkyl.

14. S-2-isopropyl-3-tert-butyl-5-hydroxymethyloxazolidine.

15. An optically active 2-aryl-3-Y-5-hydroxymethyloxazolidine in the sinister configuration wherein aryl is phenyl optionally having 1 to 3 substituents selected from the group consisting of

a. 1-3 bromo groups,

b. 1-3 -chloro groups,

c. 1-3 methyl groups,

d. 1-3 -hydroxy groups,

and

e. a methoxy group

and Y is a straight or branched chain C.sub.1 -C.sub.5 alkyl or hydroxy substituted straight or branched chain C.sub.1 -C.sub.5 alkyl.

16. An optically active 3-Y-5-(C.sub.1-16 alkylsulfonyloxymethyl)oxazolidine in the sinister configuration wherein Y is a straight or branched chain C.sub.1 -C.sub.5 alkyl or hydroxy substituted straight or branched chain C.sub.1 -C.sub.5 alkyl.

17. An optically active 3-Y-5 benzene-or substituted benzenesulfonyloxymethyl oxazolidine in the sinister configuration wherein said benzene substituents are selected from the group consisting of

a. an amino group,

b. 1-3 bromo groups,

c. 1-3 chloro groups,

d. a chloro and a nitro group,

e. a fluoro group,

f. a methoxy group,

g. 1-3 methyl groups

and

h. a nitro group,

and Y is a straight or branched chain C.sub.1 -C.sub.5 alkyl or hydroxy substituted straight or branched chain C.sub.1 -C.sub.5 alkyl.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Citi
Cerilliant
Deloitte
Medtronic
Healthtrust
Federal Trade Commission
US Army
Mallinckrodt
Covington
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot